Search company, investor...

Predict your next investment

Asset/Investment Management
FINANCE | Investment Firms & Funds
ghif.com

Investments

16

Portfolio Exits

5

Funds

4

About Global Health Investment Fund

The Global Health Investment Fund (GHIF) is an impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics, and other interventions against diseases that disproportionately burden low-income countries. The Fund provides a novel opportunity to help bring about significant improvements in the treatment and prevention of disease, in family planning, and in the reduction of maternal and child mortality, along with the prospect of a net financial return for investors.

Headquarters Location

501 Fifth Avenue Suite 1404

New York, New York, 10017,

United States

Want to inform investors similar to Global Health Investment Fund about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Global Health Investment Fund News

Micron Biomedical Secures Series A Financing to Commercialize MAP Technology for Self-Administration of Drugs and Vaccines witho...

Nov 29, 2022

Venture Capital News | Private Equity News venture capital directory | private equity directory Venture Capital Firms List / Venture Capital & Private Equity Firms and Sources Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory 2022 Newly Updated Edition Now Available! (Updated JULY 2022) VCPro Database 2022 25th Edition — a downloadable and searchable venture capital database with 6,800+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. Micron Biomedical Secures Series A Financing to Commercialize MAP Technology for Self-Administration of Drugs and Vaccines without Needles Global Health Investment Corporation and LTS Lohmann Led the Series A Financing with Participation from GRA Venture Fund ATLANTA, November 28, 2022-- Micron Biomedical, Inc. is a clinical stage life sciences company advancing its Micro Array Patch (MAP) technology for self-administration and simple, less-skilled caregiver administration of drugs and vaccines without needles. The $14 million Series A financing will support the company's development of commercial manufacturing, currently underway and establishes a strong partnership between Micron and LTS Lohmann. Micron's development pipeline includes vaccine and drug products partnered with pharma companies, foundations, and government agencies. Since inception, Micron has supported its R&D activities and shown clinical efficacy with more than $40 million in non-dilutive financing. "Micron's technology has the potential to change the way we administer many of today's currently injected drugs and vaccines" said Micron CEO Steven Damon. "We are deeply committed to bringing Micron's MAP technology-based drug and vaccine products to market, improving access and having a positive impact on patients globally. This financing, and in particular our new investors, will help us to achieve our goals". Micron's MAP technology is well suited to delivering a wide range of compounds including nucleic acids, peptides, proteins, and viruses (inactivated and live-attenuated), as well as small-molecule drugs. The benefits of Micron's MAP technology include the potential to enhance the efficacy of drugs and vaccines, ease-of-use enabling self-administration and administration by less skilled caregivers, sharps-free waste, thermal stability and small size, which together simplify storage and distribution with the potential to have products mailed to people's homes or available to pick up at the pharmacy without needing a professional to administer. These benefits render Micron's MAP technology especially desirable in case of a pandemic. About Micron Biomedical Micron is an Atlanta-based company whose MAP technology was initially developed in Dr. Mark Prausnitz's labs at Georgia Tech. Micron has further developed the technology and emerged as a leader in the field of dissolvable microarray-based, drug and vaccine delivery technology. In addition to these new investors, Micron's other partners and funders include the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), UNICEF, PATH and several private and public undisclosed pharmaceutical companies. Micron has also received support from the Georgia Research Alliance. About LTS LOHMANN LTS LOHMANN Therapie-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS") and Oral Thin Films ("OTF") for the pharmaceutical industry. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS's innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches (MAP) for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from three sites: in Andernach, Germany, West Caldwell, NJ, USA and St. Paul, MN, USA. LTS has also a representative office in Shanghai, China. About Global Health Investment Corporation A pioneer of investing in global health, GHIC has been supporting high impact biomedical innovations for nearly a decade. GHIC's Global Health Investment Fund (GHIF) financed the development of products to combat public health challenges that disproportionately affect people living in low- and middle-income countries. In 2021, GHIC entered into a 10-year venture investment partnership with the Biomedical Advanced Research and Development Authority (BARDA) focused on global health security. Contact:

Global Health Investment Fund Investments

16 Investments

Global Health Investment Fund has made 16 investments. Their latest investment was in Biolinq as part of their Series B on September 9, 2021.

CBI Logo

Global Health Investment Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/15/2021

Series B

Biolinq

$100M

Yes

6

1/6/2021

Series A

Revelation Biosciences

$9.1M

Yes

1

7/30/2020

Series C

Alydia Health

$13.9M

No

4

9/18/2019

Series D

Subscribe to see more

$99M

Subscribe to see more

10

2/18/2019

Series A

Subscribe to see more

Subscribe to see more

10

Date

9/15/2021

1/6/2021

7/30/2020

9/18/2019

2/18/2019

Round

Series B

Series A

Series C

Series D

Series A

Company

Biolinq

Revelation Biosciences

Alydia Health

Subscribe to see more

Subscribe to see more

Amount

$100M

$9.1M

$13.9M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

4

10

10

Global Health Investment Fund Portfolio Exits

5 Portfolio Exits

Global Health Investment Fund has 5 portfolio exits. Their latest portfolio exit was Revelation Biosciences on August 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/30/2021

Acq - Pending

$99M

2

3/30/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/26/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/16/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/23/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/30/2021

3/30/2021

5/26/2020

4/16/2020

10/23/2018

Exit

Acq - Pending

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Global Health Investment Fund Fund History

4 Fund Histories

Global Health Investment Fund has 4 funds, including Global Health Investment Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/2/2014

Global Health Investment Fund I

$66.77M

1

1/2/2014

Global Health Investment Fund I Offshore

$99M

10

12/19/2013

The Global Health Investment Fund

Subscribe to see more

Subscribe to see more

$99M

10

The Global Health Investment Fund II

Subscribe to see more

Subscribe to see more

10

Closing Date

1/2/2014

1/2/2014

12/19/2013

Fund

Global Health Investment Fund I

Global Health Investment Fund I Offshore

The Global Health Investment Fund

The Global Health Investment Fund II

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$66.77M

$99M

$99M

Sources

1

10

10

10

Global Health Investment Fund Team

1 Team Member

Global Health Investment Fund has 1 team member, including current President, Curt Labelle.

Name

Work History

Title

Status

Curt Labelle

Tullis Health Investors, and Investor Growth Capital

President

Current

Name

Curt Labelle

Work History

Tullis Health Investors, and Investor Growth Capital

Title

President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.